The MEST score provides earlier risk prediction in lgA nephropathy.
about
Tubular atrophy/interstitial fibrosis scores of Oxford classification combinded with proteinuria level at biopsy provides earlier risk prediction in lgA nephropathy.Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective studyComparison of different normalization strategies for the analysis of glomerular microRNAs in IgA nephropathy.Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control studySignificance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotectionCorticosteroids in IgA Nephropathy: Lessons from Recent Studies.Markers for the progression of IgA nephropathy.Biomarkers and targeted new therapies for IgA nephropathy.Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients.Is there a role for immunosuppression in immunoglobulin A nephropathy?Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.NLRP3 Localizes to the Tubular Epithelium in Human Kidney and Correlates With Outcome in IgA NephropathyRemission of Hematuria Improves Renal Survival in IgA Nephropathy.Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies.Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy.Elevated serum fibrinogen level is an independent risk factor for IgA nephropathy.IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology.The clinical relevance of plasma CD147/basigin in biopsy-proven kidney diseases.Moderator's view: Treatment of IgA nephropathy-getting comfortable with uncertainty.Clinical usefulness of the Oxford classification in determining immunosuppressive treatment in IgA nephropathy.IgA Nephropathy.Glomerular disease: Updated Oxford Classification of IgA nephropathy: a new MEST-C score.Con: STOP immunosuppression in IgA nephropathy.IgA Nephropathy: A European Perspective in the Corticosteroid TreatmentThe Emerging Role of Pathogenesis of IgA Nephropathy
P2860
Q33683223-F929DEB0-6680-431A-A886-C74E0072665EQ33893355-30708EB1-FA27-4A10-BA56-73E4F9641819Q36110820-BCAC4984-9378-44AD-AA17-68C899D95BA9Q36243259-E488517F-7A3F-4E8F-99E4-BA7B23AB8CA8Q36307746-82377AD5-DF4E-4F51-8A42-6C7449E7ACD6Q38817381-CCE18FEA-2E3D-4E38-9493-6986E94143A2Q38824816-6ECF74DB-BAF6-47C2-BCDA-4DA7EAD468F6Q38871090-5C9D0507-3B8D-42AC-99D3-D932778120D3Q38999373-C6A53B5F-1D5D-4A61-8589-2D603F0D4928Q39229309-01A14B40-9B29-41F1-8C63-30DCE6DEFFE3Q39457194-74974980-1A24-4336-97D3-76BB0E6403F0Q39839285-DF36BDDC-1EE0-4F9F-BE1E-ED3A01E5915CQ40168439-7B52841E-2D39-4990-8F42-10AC775C6B99Q40456075-43FAB7E5-7AA7-49D1-B2C6-223C30509E03Q43924057-2126F03D-8275-4BD9-80B7-D06E7BAE351CQ47100563-64852266-6CE0-4FE8-8F8E-022B985F3B27Q49477908-18636FD1-166D-4A0F-87DB-BB68317BA5D3Q49874313-2E278B17-580D-4D99-BF88-AD6C02357657Q51734842-38086704-068B-4599-95E0-C01EFE938C62Q51758616-C7ABEFBD-1CF5-4955-8797-A2D8D2EBB953Q51834649-E06AAF53-5D5A-45CE-9D8D-2210DD0CF25EQ53278365-30104125-4C1B-4FEA-8008-2DC0D4B08146Q53556768-AFC8E6E7-8FBB-40F4-9C97-2014742A4E23Q57100792-6CFD28D4-B732-4834-94DA-3A61C9875CF9Q58734688-779A5758-ABED-4F16-8F0E-40A287093BEC
P2860
The MEST score provides earlier risk prediction in lgA nephropathy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The MEST score provides earlier risk prediction in lgA nephropathy.
@ast
The MEST score provides earlier risk prediction in lgA nephropathy.
@en
type
label
The MEST score provides earlier risk prediction in lgA nephropathy.
@ast
The MEST score provides earlier risk prediction in lgA nephropathy.
@en
prefLabel
The MEST score provides earlier risk prediction in lgA nephropathy.
@ast
The MEST score provides earlier risk prediction in lgA nephropathy.
@en
P2093
P356
P1433
P1476
The MEST score provides earlier risk prediction in lgA nephropathy.
@en
P2093
Andrew M Herzenberg
Daniel C Cattran
Gabriela Espino-Hernandez
Heather N Reich
Ian S D Roberts
John Feehally
Oxford Derivation North American Validation and VALIGA Consortia
Oxford Derivation, North American Validation and VALIGA Consortia
Rosanna Coppo
Sean J Barbour
P2888
P304
P356
10.1038/KI.2015.322
P407
P577
2016-01-01T00:00:00Z